Pediatric Drug Trial Priority Should Be Vincristine/Actinomysin-D, Cmte. Says
A combination drug trial evaluating vincristine and actinomysin-D should be the top priority among off-patent drugs for a pediatric study, FDA's Pediatric Oncology Subcommittee recommended Oct. 9
You may also be interested in...
Negotiations for pediatric labeling changes would be limited to six months under a proposed bill to reauthorize the pediatric exclusivity provisions.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials